rosuvastatin / Generic mfg. - LARVOL DELTA

A Clinical Trial of Enlicitide and Rosuvastatin in Healthy Adults (MK-0616-039) (clinicaltrials.gov) - P1 | N=60 | Active, not recruiting | Sponsor: Merck Sharp & Dohme LLC | Recruiting ➔ Active, not recruiting

Enrollment closed

Comparative efficacy of locally delivered 1.2% rosuvastatin and 1.2% simvastatin gel as an adjunct to non-surgical periodontal therapy in chronic periodontitis: a clinical and microbiological assay. (PubMed, Saudi Dent J) - "The local delivery of both 1.2% simvastatin gel and 1.2% rosuvastatin gel as adjuncts to non-surgical periodontal therapy significantly improved clinical and microbiological outcomes in chronic periodontitis. While simvastatin demonstrated slightly greater absolute improvements than rosuvastatin, the overall therapeutic difference between the two statins was not statistically significant."

Journal • Dental Disorders • Periodontitis

Phase 1 Study of the Safety and Pharmacokinetics of YN001 With Rosuvastatin in Healthy Chinese Subjects (clinicaltrials.gov) - P1 | N=24 | Completed | Sponsor: Beijing Inno Medicine Co., Ltd. | Not yet recruiting ➔ Completed

Trial completion • Atherosclerosis • Cardiovascular • CNS Disorders • Vascular Neurology

A Trial in Healthy Participants to Assess Drug Interaction Potential of BGB-43395 (clinicaltrials.gov) - P1 | N=24 | Not yet recruiting | Sponsor: BeOne Medicines

New P1 trial

Clinical Study of PCSK9 Inhibitors for Preventing Early Neurological Deterioration in Branch Atheromatous Disease (ChiCTR) - P4 | N=152 | Not yet recruiting | Sponsor: The First Affiliated Hospital of Dalian Medical University; The First Affiliated Hospital of Dalian Medical University

New P4 trial • Cardiovascular • Ischemic stroke

Rhabdomyolysis resulting from the interaction of rosuvastatin and abiraterone: A case study. (PubMed, Semin Oncol) - "Subsequent pharmacogenetic testing showed the patient was heterozygous for SLCO1B1*15, a variant of the SLCO1B1 gene encoding OATP1B1, which results in moderately reduced OATP1B1 transport activity. Considering the high frequency of statin prescribing, clinicians should be aware of the possible drug-drug interactions between statins and abiraterone and the associated risk of rhabdomyolysis, which is also affected by genetic differences."

Journal • Acute Kidney Injury • Castration-Resistant Prostate Cancer • Fatigue • Genito-urinary Cancer • Musculoskeletal Pain • Nephrology • Oncology • Pain • Prostate Cancer • Renal Disease • Solid Tumor • SLCO1B1

Novel inhibitors of BCRP found among drugs used in the treatment of cancer. (PubMed, Eur J Pharm Sci) - "Moreover, the model suggested that midostaurin, cabozantinib, and alpelisib could almost fully inhibit intestinal BCRP, nearly doubling rosuvastatin exposure (1.83- to 1.94-fold). Entrectinib, alpelisib, flutamide, abiraterone, and capecitabine were predicted to increase rosuvastatin exposure by 1.45- to 1.63-fold through BCRP inhibition. FAERS analysis indicated a higher frequency of rhabdomyolysis reports when abiraterone was co-administered with rosuvastatin compared with all reports without abiraterone, with a reporting odds ratio of 17.3. This study identified multiple previously unrecognized BCRP inhibitors, highlighting the potential for clinically relevant BCRP‑mediated drug-drug interactions in oncology patients."

Journal • Breast Cancer • Oncology • Solid Tumor

PBPK Modeling of Coproporphyrin I Reveals Frailty-Associated Changes in Hepatic OATP1B1 Function in Chinese Adults. (PubMed, Clin Pharmacokinet) - "This study provides a PBPK framework for interpreting CPI variability and quantifying frailty-associated changes in OATP1B1 function in Chinese adults, supporting biomarker-informed precision dosing of OATP1B1 substrate drugs."

Journal • Geriatric Disorders

Real-world patterns in lipid profile testing and lipid-lowering therapy in hospitalized patients: The Jurasz Lipid Study. (PubMed, Int J Cardiol Cardiovasc Risk Prev) - "Statin monotherapy remained the standard of care, with atorvastatin and rosuvastatin being the most frequently used agents. Statin monotherapy remained the cornerstone of LLT. Statin with ezetimibe was the most common therapeutic combination."

Journal • Real-world evidence • Atherosclerosis • Cardiovascular • Pediatrics

ROS-responsive bionanodrug for atherosclerosis therapy via regulating glycolipid metabolism and cell crosstalk. (PubMed, J Control Release) - "Rosuvastatin (RSV), a first-line drug with lipid-lowering activity, fails to adequately modulate the inflammatory microenvironment of atherosclerotic plaques...Compared with free drugs, this strategy exhibited superior efficacy in regulating the plaque microenvironment by inhibiting lipid deposition. In summary, this work introduces a novel plaque environment-activated prodrug platform, providing valuable insights for clinical translation of AS therapy."

Journal • Atherosclerosis • Cardiovascular • Inflammation • Metabolic Disorders • Respiratory Syncytial Virus Infections • APOE

Changes in LDL-C levels among primary health care patients with hypertension, coronary artery disease, and diabetes during a 36-month follow-up. (PubMed, Scand J Prim Health Care) - "During a period of increasing pharmacotherapeutic opportunities, this study, conducted in everyday clinical practice suggests that common lipid-lowering medications (atorvastatin and rosuvastatin) are most frequently used for primary health care patients, and are associated with a significant decrease in LDL-C levels. A greater decrease was observed among patients with higher baseline LDL-C values. Despite decreases in LDL-C, this study suggests that the gap remains between guideline-recommended treatment targets and achieved LDL-C levels."

Journal • Atherosclerosis • Cardiovascular • Coronary Artery Disease • Diabetes • Dyslipidemia • Hypertension • Hypotension • Metabolic Disorders

A microdose cocktail and population pharmacokinetic study suggests potentially reduced CYP3A and P-gp activities in type 2 diabetes. (PubMed, Front Pharmacol) - "The activities of CYP3A and transporters P-gp, OATP and BCRP were evaluated in type 2 diabetes patients and healthy volunteers (HVs) following a single oral dose of five probe drugs (midazolam, dabigatran etexilate, pitavastatin, rosuvastatin, and atorvastatin). Additionally, factors such as sex, BCRP genotype, and Clostridium_XlVb partly explained the IIV in probe drugs exposure. The findings regarding altered DMET activities and identified influence factors help to identify specific drug classes that may warrant closer clinical attention in type 2 diabetes patients."

Journal • PK/PD data • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

A Case of Statin-Induced Fulminant Hepatitis Presenting as Septic Shock and Multiorgan Failure. (PubMed, Cureus) - "Statins are among the most widely prescribed medications for hyperlipidemia, with drug-induced liver injury (DILI) being a rare adverse event. Here, we report a case involving a 69-year-old female patient who developed fulminant liver failure following an overdose of rosuvastatin...Despite comprehensive critical care, including advanced supportive and rescue interventions, the patient's condition deteriorated, and she did not survive. This underscores the potential lethality of statin overdose and the importance of medication safety, early recognition, and prevention strategies."

Journal • Critical care • Dyslipidemia • Hepatology • Inflammation • Liver Failure • Pain • Septic Shock

Comparative effects of atorvastatin and rosuvastatin on inflammatory biomarkers: a systematic review and meta-analysis of randomized head-to-head trials. (PubMed, BMC Cardiovasc Disord) - "Rosuvastatin showed a modest but statistically significant advantage over atorvastatin in lowering CRP, especially in patients with higher baseline inflammation or hypertension. Evidence for other biomarkers remains inconclusive. Tailoring statin therapy to patient profiles may optimize benefits."

Biomarker • Clinical • Head-to-Head • Journal • Retrospective data • Review • Cardiovascular • Hypertension • Oncology • CRP • IL6 • TNFA

High-Intensity Statins and the Post-Discharge Clinical Outcomes at 1 Year After Percutaneous Coronary Intervention: Insights From STOPDAPT-3. (PubMed, Circ Rep) - "We performed a post hoc analysis of STOPDAPT-3, which compared 1-month aspirin-free prasugrel monotherapy followed by clopidogrel monotherapy with 1-month dual antiplatelet therapy (DAPT) followed by aspirin monotherapy in patients with ACS or a high bleeding risk undergoing PCI. High-intensity statins were defined as the maximum approved dose of strong statins in Japan (e.g., rosuvastatin 10 mg, atorvastatin 20 mg, or pitavastatin 4 mg)...The 1-year post-discharge cumulative incidence of cardiovascular events was similar between patients who received high-intensity statins and those who did not (3.90% vs. 4.27%, P=0.51; adjusted HR 1.03; 95% CI 0.74-1.44; P=0.84). In STOPDAPT-3, high-intensity statin therapy at discharge was not associated with a reduced risk of cardiovascular events 1 year after PCI, under the limitations of having no laboratory test or prescription data available during the follow up."

Clinical data • Journal • Acute Coronary Syndrome • Cardiovascular • Coronary Artery Disease • Dyslipidemia

A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin and Placebo on LDL-C in LLT-naïve Patients. (clinicaltrials.gov) - P3 | N=600 | Recruiting | Sponsor: AstraZeneca | Not yet recruiting ➔ Recruiting

Enrollment open • Dyslipidemia

A Study Investigating the Safety of RO7795081 and the Effect of RO7795081 on How the Body Processes Pitavastatin and Rosuvastatin in Otherwise Healthy Overweight or Obese Adult Participants (clinicaltrials.gov) - P1 | N=40 | Active, not recruiting | Sponsor: Hoffmann-La Roche | Recruiting ➔ Active, not recruiting

Enrollment closed • Genetic Disorders • Obesity

Efficacy and Safety of Fixed-Dose Combination Therapy with Cilostazol and Rosuvastatin in Patients with Symptomatic Lower Extremity Peripheral Artery Disease: A Multicenter Randomized Controlled Trial. (PubMed, Cardiovasc Drugs Ther) - P3 | "In patients with symptomatic PAD, the addition of cilostazol to rosuvastatin significantly improved patient-reported health status and provided additional favorable effects on atherogenic lipid profiles beyond rosuvastatin therapy alone."

Journal • Cardiovascular • Peripheral Arterial Disease • APOB

Targeted drug delivery of rosuvastatin via nanoemulgel: A step towards more effective rheumatoid arthritis therapy. (PubMed, Int Immunopharmacol) - "The animals treated with RSV-NEG exhibited anti-inflammatory potential along with significantly reduced (****p < 0.0001) paw thickness and arthritis scores compared to the negative control group. The promising findings with permeability after topical application and anti-inflammatory potential emphasize the ability of RSV-NEG to manage RA effectively."

Journal • Immunology • Inflammation • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology

The HMG-CoA Reductase Inhibitor Fluvastatin Promotes Th2-Skewed Immune Responses by Modulating Dendritic Cell Differentiation. (PubMed, Genes Cells) - "This effect was not shared by rosuvastatin, suggesting that lipophilicity-dependent cellular uptake influences immunomodulatory potency. These functional changes were accompanied by alterations in DC surface molecule expression, although their causal contribution remains to be established. These findings indicate that continuous fluvastatin exposure during DC differentiation is associated with an altered DC phenotype and enhanced Th2-polarizing capacity."

Journal • CD4 • CSF2 • IFNG • IL4

Integrative Cross-platform Analysis of Kinase Inhibitor Effects on Statin-relevant Cardioprotective Pathways in Human Cardiomyocytes. (PubMed, Cancer Genomics Proteomics) - "KI effects on statin-relevant pathways were pathway-specific. Anti-fibrotic concordance and nilotinib-associated NF-κB upregulation are hypothesis-generating candidates for experimental validation."

Journal • Cardiovascular • Oncology

Identification of Gln422 in transmembrane domain 9 as a key amino acid residue for the selective transport of ginsenoside Re by organic anion transporting polypeptide 1B3. (PubMed, Drug Metab Dispos) - "However, it only has a trivial effect on the transport of estradiol-17β-glucuronide, estrone-3-sulfate, and rosuvastatin...The naturally occurring Q422H variant may largely compromise OATP1B3's function and thus impair the hepatobiliary excretion of these ginsenosides. These findings would advance our knowledge of the molecular mechanism for OATP1B3's selectivity toward protopanaxatriol-type ginsenosides."

Journal

Lipid-lowering agent use and changes to sleep. (PubMed, Sleep Med) - "The use of atorvastatin may be associated with negative impacts to patients' sleep, though the magnitude of change is small. Clinicians should be aware of these effects and counsel patients accordingly."

Journal • CNS Disorders • Obstructive Sleep Apnea • Respiratory Diseases • Sleep Disorder

The impact of concomitant use of rosuvastatin or atorvastatin plus clopidogrel on the platelet inhibition and clinical outcomes in acute large-vessel minor stroke or TIA: A randomized controlled multi-center trial, the ROCATIS-1 trial. (PubMed, Ther Adv Neurol Disord) - "There were no significant differences between rosuvastatin and atorvastatin regarding drug-related side effects. Our findings are hypothesis-generating and require confirmation in a double-blinded, multinational randomized trial before they can inform practice."

Clinical • Clinical data • Journal • Cardiovascular • Hematological Disorders • Ischemic stroke

Selective statin therapy and nasal staphylococcal colonisation: a retrospective case-control study. (PubMed, Eur J Clin Microbiol Infect Dis) - "Statin therapy, particularly atorvastatin and rosuvastatin at moderate to high dose intensities, was associated with increased nasal S. aureus colonisation. These findings may have implications for infection prevention in high-risk patients, though they do not diminish the established cardiovascular benefits of statins. Prospective studies are required to confirm causality, elucidate mechanisms, and determine whether these findings should inform screening or decolonisation strategies."

Journal • Retrospective data • Cardiovascular • Diabetes • Dyslipidemia • Infectious Disease • Metabolic Disorders